Photos: 

Some evaluation reports are public and can be downloaded from this website, while others are restricted to MSF users and can only be accessed via Tukul. This limitation is mainly due to the sensitive nature of the operational contexts and the resulting content. However, there are internal discussions about making all evaluation reports publicly searchable. If you are an MSF association member, reports are made available on various associate platforms such as www.insideOCB.com.

Country/Region

This document describes the project Lessons identified at the end of the market entry planning phase for MSF in Finland. It summarises the successes and challenges encountered during the project, lists the learning themes arising from these successes and challenges, and includes a set of lessons derived from an analysis of these learning points. The Annex contains a proposed (brief) framework with criteria and pre-requisites for a successful Market Entry Plan in MSF based on this experience. NOTE: This is not an evaluation and therefore there is no ambition for independent judgement.

This Retrospect was facilitated by the Stockholm Evaluation Unit on behalf of the Project Team. The report has been prepared by Timothy McCann.
30/10/2017

This report is a review of advocacy within the MSF movement from 2010-2015. Commissioned by the core ExCom, the aim of this review was to explore the effectiveness of MSF advocacy and produce recommendations to improve its approach, coordination and organization in support to operations within the movement. Two external evaluation consultants, Glenn O’Neil and Liesbeth Schockaert, conducted the review with the support of Nirupama Sarma who carried out a complementary review of the Access Campaign (AC).

This publication was produced at the request of MSF International, under the management of the Vienna Evaluation Unit. It was prepared independently by Glenn O'Neil and Liesbeth Schockaert, with contributions from Nirupama Sarma.
14/09/2016

This evaluation assesses the results of the entire OCA Wardher project from 2008 – 2015, drawing lessons from this engagement, including on how to best engage in conflict prone and similar fragile context in the future. It is also an opportunity for MSF to reflect on this project for future interventions.  

This publication was produced at the request of MSF OCA, under the management of the Stockholm Evaluation Unit. It was prepared independently by Catherine Lalonde and Jared Mala.
21/04/2016

This evaluation aimed at gaining perspective on and learning from current partnership practices, informing the debate on MSF’s policy on partnerships and providing guidance for future engagement. Four separate field evaluations in DRC, Kenya, Niger and North Korea as well as a desk review of seven additional partnerships have been conducted. The report provides good practice examples and practical recommendations.

Karima Hammadi and Annie Désilets
01/02/2012

Through an analysis of the events that have marked MSF’s history since 2003, this series of case studies and historical accounts describes the evolution of MSF's humanitarian ambitions, the resistance to these ambitions and the political arrangements that overcame this resistance (or that failed to do so).

edited by Claire Magone, Michaël Neuman, Fabrice Weissman
22/11/2011

The overall objective of the evaluation is to identify and describe factors and issues to consider when planning implementation or continuation of Remote Control Programmes (RCPs) as an alternative to cancelling Médecins Sans Frontières (MSF) programme implementation in a particular region/ country.

Martin Braaksma and Mzia Turashvili
01/06/2009

The Bosnia programme was one of the largest programmes MSF has implemented so far, and it was the first major operation MSF executed in an European environment. There was a widely shared view that the programme had gone “out of control”. As a result, many within MSF considered drug distribution in general as being beyond the scope of MSF. The dominance of drug distribution in the programme was perceived to be in contradiction with the medical identity of MSF.

Van de Putte, B. and Maslesa, L.
01/04/1998